Nexalin Launches Pivotal Insomnia Trial Aimed at FDA Clearance

Event summary

  • Nexalin Technology, Inc. announced a 150-patient, triple-blinded, sham-controlled trial for its HALO™ Clarity device targeting moderate to severe insomnia.
  • The study, conducted in collaboration with Lindus Health, is designed to support a planned de novo FDA submission.
  • The trial will be fully decentralized, utilizing Nexalin’s NeuroCare virtual clinic for remote treatments and assessments.
  • HALO™ Clarity leverages Nexalin’s proprietary 15 mA Deep Intracranial Frequency Stimulation (DIFS™) technology.
  • The study builds on prior clinical data, including a 120-participant study published in the Journal of Psychiatric Research.

The big picture

Nexalin’s pivotal trial for HALO™ Clarity represents a strategic push into the underserved insomnia market, where drug-free treatment options are in high demand. The company’s DIFS™ technology aims to differentiate itself from conventional transcranial stimulation by targeting deeper brain structures. Success in this trial could validate Nexalin’s broader platform for neuropsychiatric indications and set the stage for regulatory approvals in other high-prevalence conditions.

What we're watching

Regulatory Pathway
Whether Nexalin can successfully navigate the FDA de novo submission process for HALO™ Clarity.
Clinical Execution
The pace at which Nexalin enrolls and completes the 150-patient trial, given the decentralized nature of the study.
Market Adoption
How the potential FDA clearance could position HALO™ Clarity in the multi-billion-dollar insomnia therapeutics market.

Related topics

Biotechnology